[go: up one dir, main page]

WO2003000191A3 - Composition comprenant des glycosaminoglycanes et des inhibiteurs d'hyaluronidase destinee au traitement d'articulations arthritiques - Google Patents

Composition comprenant des glycosaminoglycanes et des inhibiteurs d'hyaluronidase destinee au traitement d'articulations arthritiques Download PDF

Info

Publication number
WO2003000191A3
WO2003000191A3 PCT/US2002/019718 US0219718W WO03000191A3 WO 2003000191 A3 WO2003000191 A3 WO 2003000191A3 US 0219718 W US0219718 W US 0219718W WO 03000191 A3 WO03000191 A3 WO 03000191A3
Authority
WO
WIPO (PCT)
Prior art keywords
hyaluronic acid
composition
hyaluronidase inhibitor
preferred
hyaluronidase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/019718
Other languages
English (en)
Other versions
WO2003000191A2 (fr
Inventor
Jonathan Thompson
Anna Gosiewska
Susan Niemiec
Sridevi Dhanaraj
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DePuy International Ltd
Original Assignee
DePuy International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DePuy International Ltd filed Critical DePuy International Ltd
Priority to JP2003506637A priority Critical patent/JP2005521629A/ja
Priority to EP02739947A priority patent/EP1423081A4/fr
Priority to CA002451248A priority patent/CA2451248A1/fr
Publication of WO2003000191A2 publication Critical patent/WO2003000191A2/fr
Anticipated expiration legal-status Critical
Publication of WO2003000191A3 publication Critical patent/WO2003000191A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une composition et une méthode de traitement de l'arthrite, ladite composition comprenant au moins un glycosaminoglycane combiné à au moins un inhibiteur d'hyaluronidase. Dans un mode de réalisation préféré, la présente invention concerne une composition et une méthode de traitement de l'arthrite, ladite composition comprenant au moins un glycosaminoglycane qui comprend au moins de l'acide hyaluronique combiné à au moins un inhibiteur d'hyaluronidase sélectionné dans le groupe constitué d'héparane sulfate, de dextrane sulfate et de xylose sulphate. Dans un autre mode de réalisation préféré encore, la présente invention concerne une composition et une méthode de traitement de l'arthrite, ladite composition comprenant de l'acide hyaluronique co-encapsulé avec un inhibiteur d'hyaluronidase présent dans les liposomes. L'acide hyaluronique présent dans la composition confère les propriétés de viscosupplément à l'articulation. La fonction de l'inhibiteur d'hyaluronidase est d'agir en tant qu'un conservateur, et de protéger l'acide hyaluronique contre la dégradation prématurée au niveau de l'articulation. L'encapsulation liposomale et la libération de ladite composition sert de dépôt à libération lente pour l'acide hyaluronique et de l'inhibiteur d'hyaluronidase. Ladite invention concerne par conséquent un moyen d'administration stable et de longue durée d'acide hyaluronique (HA) de poids moléculaire élevé au niveau de l'articulation. L'efficacité thérapeutique de l'acide hyaluronique encapsulé dans le liposome avec l'inhibiteur d'hyaluronidase est supérieur à une simple injection d'acide hyaluronique. La méthode de traitement préférée est une injection intra-articulaire d'un mélange d'acide hyaluronique et d'un inhibiteur d'hyaluronidase, éventuellement encapsulés dans des liposomes. Le traitement est plus efficace que les traitements actuellement disponibles reposant sur le seul HA.
PCT/US2002/019718 2001-06-25 2002-06-20 Composition comprenant des glycosaminoglycanes et des inhibiteurs d'hyaluronidase destinee au traitement d'articulations arthritiques Ceased WO2003000191A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2003506637A JP2005521629A (ja) 2001-06-25 2002-06-20 関節炎の関節を治療するためのグリコサミノグリカンとヒアルロニダーゼ阻害剤を含んで成る組成物
EP02739947A EP1423081A4 (fr) 2001-06-25 2002-06-20 Composition comprenant des glycosaminoglycanes et des inhibiteurs d'hyaluronidase destinee au traitement d'articulations arthritiques
CA002451248A CA2451248A1 (fr) 2001-06-25 2002-06-20 Composition comprenant des glycosaminoglycanes et des inhibiteurs d'hyaluronidase destinee au traitement d'articulations arthritiques

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30073401P 2001-06-25 2001-06-25
US60/300,734 2001-06-25
US74102A 2002-06-06 2002-06-06
USDEP-741 2002-06-06

Publications (2)

Publication Number Publication Date
WO2003000191A2 WO2003000191A2 (fr) 2003-01-03
WO2003000191A3 true WO2003000191A3 (fr) 2004-03-11

Family

ID=26668090

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/019718 Ceased WO2003000191A2 (fr) 2001-06-25 2002-06-20 Composition comprenant des glycosaminoglycanes et des inhibiteurs d'hyaluronidase destinee au traitement d'articulations arthritiques

Country Status (4)

Country Link
EP (1) EP1423081A4 (fr)
JP (1) JP2005521629A (fr)
CA (1) CA2451248A1 (fr)
WO (1) WO2003000191A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109758607A (zh) * 2019-03-08 2019-05-17 宁夏妙朗生物科技有限公司 抵抗透明质酸酶水解的交联透明质酸凝胶

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4703948B2 (ja) * 2003-05-20 2011-06-15 丸善製薬株式会社 抗アレルギー剤、抗老化剤及び抗老化用皮膚外用剤
CA2577022A1 (fr) * 2004-08-13 2006-02-23 Angiotech International Ag Compositions et methodes utilisant de l'acide hyaluronique
AU2013270451B2 (en) * 2005-10-03 2016-05-12 Mark A. Pinsky Compositions and methods for improved skin care
AU2006299421B2 (en) 2005-10-03 2013-01-31 Mark A. Pinsky Compositions and methods for improved skin care
EP2543340A1 (fr) * 2006-05-19 2013-01-09 Trustees Of Boston University Nouveaux polymères hydrophiles utilisés en tant que gels et lubrifiants à usage médical
US20100323985A1 (en) * 2007-05-11 2010-12-23 Marc Moutet Pharmaceutical or cosmetic preparations for topical and/or parenteral application, preparation methods thereof and use of same
US20110263521A1 (en) * 2007-05-11 2011-10-27 Marc Moutet Pharmaceutical or cosmetic preparations for topical and/or parenteral application, preparation methods thereof and use of same
US8394782B2 (en) 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having increased longevity
ITMI20072348A1 (it) 2007-12-17 2009-06-18 Medichem Srl Metodo per la rigenerazione cellulare di acido ialuronico e relativa composizione cosmetica
MX2010012326A (es) * 2008-05-19 2010-12-01 Univ North Carolina Metodos y composiciones que comprenden nuevos lipidos cationicos.
ITMI20090779A1 (it) * 2009-05-08 2010-11-08 Vitrupharm Srl Composizioni nutrizionali a base di resveratrolo cisteina o suoi derivati o metaboliti e astaxantina
US8557275B2 (en) 2009-07-23 2013-10-15 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA
US9238043B2 (en) 2009-07-23 2016-01-19 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using algae based oils
US9913810B2 (en) 2009-07-23 2018-03-13 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using phospholipids and astaxanthin
US9402857B2 (en) 2009-07-23 2016-08-02 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using low molecular weight hyaluronic acid and astaxanthin
US9216164B2 (en) 2009-07-23 2015-12-22 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA
US9399047B2 (en) 2009-07-23 2016-07-26 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using phospholipids and roe extract
US8481072B2 (en) 2009-07-23 2013-07-09 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
BR112012011336A2 (pt) 2009-10-22 2018-10-16 Api Genesis Llc Composições compreendendo flavonoides, seu método de preparação, adesivo para aplicação de flavonoide, métodos de produção de flavonoide hidratado,métodos de preparação de formulação tópica, e uso de flavonoide
WO2011160146A1 (fr) * 2010-06-23 2011-12-29 Croma-Pharma Gesellschaft M.B.H. Préparation pharmaceutique contenant du dextrane et de l'hyaluronate de sodium pour le traitement de troubles articulaires
US8716204B2 (en) 2010-07-27 2014-05-06 Zimmer, Inc. Synthetic synovial fluid compositions and methods for making the same
ITRM20100614A1 (it) * 2010-11-24 2012-05-25 D M G Italia S R L Preparazioni farmaceutiche dell acido 18 beta glicirretico e/o di suoi derivati per infiltrazioni intrarticolari per il trattamento delle artropatie infiammatorie
FR2991876B1 (fr) * 2012-06-13 2014-11-21 Vivacy Lab Composition, en milieu aqueux, comprenant au moins un acide hyaluronique et au moins un sel hydrosoluble de sucrose octasulfate
EP3334451B1 (fr) * 2015-08-13 2020-10-28 Stoffel, Bertrand Composition pour la protection de polysaccharides dans des articulations
DE102016208567A1 (de) * 2016-05-19 2017-11-23 Heraeus Medical Gmbh Polymerlösung zur Viscosupplementation
KR102607729B1 (ko) 2017-08-22 2023-11-29 뫼비우스 메디칼 리미티드 관절 윤활용 리포좀 제형
WO2024154134A1 (fr) 2023-01-19 2024-07-25 Moebius Medical Ltd. Composition liposomale à action prolongée pour le traitement de la douleur dans des troubles articulaires

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4239754A (en) * 1976-10-23 1980-12-16 Choay, S.A. Liposomes containing heparin and a process for obtaining them
US4743596A (en) * 1987-06-16 1988-05-10 Lapin Alfred R Anti-arthritic preparation
US6136795A (en) * 1998-11-18 2000-10-24 Omni Nutraceuticals, Inc Dietary regimen of nutritional supplements for relief of symptoms of arthritis
US6232315B1 (en) * 1998-09-28 2001-05-15 Merck & Co., Inc. Method for treating inflammatory diseases by administering a thrombin inhibitor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK191889D0 (da) * 1989-04-20 1989-04-20 Bukh Meditec Kosmetisk middel
AU5089400A (en) * 1999-06-07 2000-12-28 University Of Sheffield, The Arthritis treatment

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4239754A (en) * 1976-10-23 1980-12-16 Choay, S.A. Liposomes containing heparin and a process for obtaining them
US4743596A (en) * 1987-06-16 1988-05-10 Lapin Alfred R Anti-arthritic preparation
US6232315B1 (en) * 1998-09-28 2001-05-15 Merck & Co., Inc. Method for treating inflammatory diseases by administering a thrombin inhibitor
US6136795A (en) * 1998-11-18 2000-10-24 Omni Nutraceuticals, Inc Dietary regimen of nutritional supplements for relief of symptoms of arthritis

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109758607A (zh) * 2019-03-08 2019-05-17 宁夏妙朗生物科技有限公司 抵抗透明质酸酶水解的交联透明质酸凝胶
CN109758607B (zh) * 2019-03-08 2021-07-27 宁夏妙朗生物科技有限公司 抵抗透明质酸酶水解的交联透明质酸凝胶

Also Published As

Publication number Publication date
CA2451248A1 (fr) 2003-01-03
JP2005521629A (ja) 2005-07-21
EP1423081A4 (fr) 2005-05-25
EP1423081A2 (fr) 2004-06-02
WO2003000191A2 (fr) 2003-01-03

Similar Documents

Publication Publication Date Title
WO2003000191A3 (fr) Composition comprenant des glycosaminoglycanes et des inhibiteurs d'hyaluronidase destinee au traitement d'articulations arthritiques
CA2390824A1 (fr) Compositions aqueuses, acides, antisudorifiques stabilisees et methodes y ayant trait
WO2003063799A3 (fr) Compositions et methodes d'inhibition systemique de la degradation du cartilage
WO2000032196A3 (fr) Inhibiteurs de proteines servant a transporter plusieurs medicaments
WO2003079972A3 (fr) Systemes de distribution d'agents actifs et methodes de protection et d'administration d'agents actifs
CA2289505A1 (fr) Composition pour traitement capillaire
WO1999062462A3 (fr) Compositions de soin capillaire
WO2001015678A3 (fr) Utilisation topique d'agonistes des kappa opioides afin de traiter les douleurs oculaires
BR0311939A (pt) composição farmacêutica, método para tratar inflamação em um mamìfero e uso de uma citocina protetora de tecido orgánico
DE69842021D1 (de) Aminozucker, Chondroitin und S-Adenosylmethionin enthaltende Zusammensetzungen
WO2003053336A3 (fr) Procedes de traitement de malaises neurovasculaires peripheriques
MY130477A (en) Pharmaceutical compositions for the treatmen of mucositis, stomatitis and behcet,s syndrome
CA2371372A1 (fr) Produits de conservation du bois a base d'oxydes d'amine / de cuivre
WO2001052833A8 (fr) Compositions permettant la liberation d'antagoniste de cortisol
WO2005030753A3 (fr) Agents therapeutiques utiles pour traiter la douleur
EE04953B1 (et) Tsinkhaluronaadi kasutamine ja meetod ravimkoostise valmistamiseks
AR018357A1 (es) Acido petroselinico en una composicion y en un metodo para reducir o eliminar la irritacion o la picazon de la piel inducida por los alfa-hidroxiacidos
GB2329585A (en) A barrier cream comprising hexamethylenetetramine or derivative thereo
WO2001082938A3 (fr) Compositions utiles pour le traitement de pathologies des tissus conjonctifs
WO2001091774A3 (fr) Traitement des ulceres chroniques
WO2006118980A3 (fr) Composes d'ammonium quaternaire a longue chaine en tant qu'agents de traitement du bois
WO2025019344A3 (fr) Combinaisons comprenant un inhibiteur d'atr et un inhibiteur de parp et leurs méthodes d'utilisation
WO2000072835A3 (fr) Application topique d'agents muscariniques et opioides conçus pour traiter les bourdonnements d'oreilles
WO2003032925A3 (fr) Inhibiteurs de glycosulfopeptide et procedes d'utilisation associes
CA2529441A1 (fr) Utilisation d'acide hyaluronique dans la preparation de compositions pour le traitement d'aphtes de la cavite buccale

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003506637

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2451248

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002312564

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002739947

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002739947

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002739947

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)